Guidelines for Complications of Cancer Treatment Vol VIII Part B

Registry of Patients. We computed IRs of IP among breastcancer patients and age-standardised incidence rate ratios(SIRs) comparing breast cancer patients with the generalpopulation. During follow-up, 28 breast cancer patients wereregistered with an IP diagnosis (IR=17.3 per 100,000 personyears(p-y) (95% confidence intervals (95% CI): 11.7-24.6)).When follow-up was restricted to 1 year after the first breastcancer diagnosis, eight patients with IP were identified(IR=23.4 per 100,000 p-y (95% CI: 11.0-44.1)). The SIRcomparing breast cancer patients with the general populationwas 8.4 (95% CI: 5.7-11.9). Thus, although IP is a rare adverseevent among breast cancer patients, its risk is substantiallyhigher than that in the general population.J Thorac Oncol. 2007 Sep;2(9):864-74.Predicting risk of radiation-induced lung injury.Madani I, De Ruyck K, Goeminne H, De Neve W, ThierensH, Van Meerbeeck J.Department of Radiotherapy, Ghent University Hospital,Ghent, Belgium. indira@krtkg1.ugent.beRadiation-induced lung injury (RILI) is the most common,dose-limiting complication of thoracic radio- andradiochemotherapy. Unfortunately, predicting which patientswill suffer from this complication is extremely difficult. Ideally,individual phenotype- and genotype-based risk profiles shouldbe able to identify patients who are resistant to RILI and whocould benefit from dose escalation in chemoradiotherapy. Thiscould result in better local control and overall survival. Wereview the risk predictors that are currently in clinical use—dosimetric parameters of radiotherapy such as normal tissuecomplication probability, mean lung dose, V20 and V30—aswell as biomarkers that might individualize risk profiles. Thesebiomarkers comprise a variety of proinflammatory and323